AskBio, part of the Bayer Group, commences a Phase II clinical study, GenePHIT, targeting the treatment of Congestive Heart Failure (CHF).

Elicio Therapeutics, Inc. announced the first participant treated in a Phase 2 trial of ELI-002 7P, an adjuvant monotherapy for KRAS-mutant pancreatic ductal adenocarcinoma.

Aclaris Therapeutics, working on immune-related treatments, shared initial Phase 2b results. They tested ATI-1777, a new topical JAK 1/3 inhibitor, on atopic dermatitis patients.

EyePoint Pharma reports initial participant receives treatment in early-stage VERONA study assessing EYP-1901 for diabetic eye swelling.

Ariceum Therapeutics has submitted an application for a Clinical Trial Authorization (CTA) in the UK to conduct initial trials of its novel Iodine-123 tagged PARP inhibitor, targeting recurrent glioblastoma patients.

Mirati Therapeutics, Inc. announced today that the European Commission has granted conditional approval for their medication, KRAZATI® (adagrasib).

Xeris Biopharma has announced a global licensing agreement with Amgen for a subcutaneous teprotumumab injection using its XeriJect® system for Thyroid Eye Disease.

The European Commission has approved STADA and Alvotech's biosimilar Uzpruvo® (AVT04), similar to Stelara® (ustekinumab), for marketing.

Verge Genomics has announced the start of its Phase 1b trial for VRG50635, a potential treatment for amyotrophic lateral sclerosis (ALS), covering both sporadic and familial forms.

Corbus Pharmaceuticals Holdings, Inc., focused on precision oncology, announced FDA approval for its CRB-601 drug application.

Constant Therapeutics LLC, specializing in biopharmaceuticals, announced the first patient dosed in their Phase 2 trial of TXA127, a peptide therapy aimed at improving post-stroke recovery.

Pfizer and Genmab announced the FDA has accepted their supplemental application for TIVDAK.